What did @millennialrx actually say?
The creator, identifying as a pharmacist, walked viewers through a Mounjaro (tirzepatide) auto-injector demonstration. Key claims: keep the pen refrigerated, remove it about an hour before injecting, clean the skin around the injection site, place the pen before unlocking it, press and hold until you hear a click, wait 10 seconds if you can't hear it, and dispose in a sharps container. They also said that "some blood comes out after you inject yourself" is normal and "does commonly happen." The video uses a demo pen, which is worth noting, since the physical feedback on a demo differs from a loaded pen.
This is broadly a how-to injection technique video, not a pharmacology deep-dive. The creator keeps it accessible, which has real value for first-time users who are often sent home with a pen and minimal hands-on instruction.
Does the science back this up?
Mostly, yes. The core injection mechanics align with Eli Lilly's prescribing information and documented best practices for subcutaneous auto-injectors. The 10-second hold recommendation is supported by device design, and the injection-site rotation guidance is consistent with published GLP-1 administration literature.
The one-hour warm-up recommendation is where things get slightly murky. Lilly's official Mounjaro instructions say to let the pen come to room temperature for 30 minutes before injecting, not 60. Injecting cold medication can increase discomfort and potentially affect dispersion at the subcutaneous tissue level, which is why warming matters. But doubling the recommended time isn't dangerous; it's just imprecise. Research on subcutaneous biologics more broadly, including insulin analogues, suggests room-temperature equilibration reduces injection-site pain (Frid et al., 2016, Diabetes Technology and Therapeutics), but the exact window is device-specific. For Mounjaro specifically, the 30-minute window from Lilly's own labeling is the reference point.
What did they get wrong (or right)?
Let's start with what they got right, because there's real substance here. The sharps container reminder is important and often skipped in social media content. The "place it first, then unlock" sequence is correct and reduces accidental activation. The 10-second hold instruction for users who are hard of hearing is a thoughtful addition that goes beyond the basics.
The warm-up timing is off. Saying "an hour before" instead of the labeled 30 minutes is a minor but real inaccuracy. For a pharmacist creating instructional content at 354,000 views, precision matters.
The belly button guidance is also vague in a way that could cause problems. The creator says to put "two fingers together" next to the navel and inject nearby. But Lilly's labeling specifies injecting at least 2 inches away from the navel, and avoiding the area directly around it. Two fingers placed adjacent to the belly button does not reliably produce 2 inches of clearance for all body types. This is a small but consequential gap in the instruction.
Calling bleeding at the injection site "common" without context is somewhat misleading. Minor pinpoint bleeding from capillary nicks is normal. Significant bruising or bleeding warrants attention. The creator does say to "let your doctor know," which is appropriate, but framing it as something that "commonly happens" without distinguishing between minor and notable bleeding could cause users to dismiss something worth flagging.
What should you actually know?
If you are using Mounjaro, the most reliable source of injection guidance remains the Prescribing Information and Medication Guide provided with your prescription. Eli Lilly also provides instructional videos on their official platform. A 354,000-view TikTok from a credentialed creator is a useful supplement, not a substitute.
A few specifics worth knowing: Mounjaro is approved for type 2 diabetes; Zepbound is the same molecule (tirzepatide) approved for chronic weight management. These are not interchangeable from an insurance or indication standpoint. The creator correctly identifies Mounjaro's weekly dosing schedule. Injection sites can be the abdomen, thigh, or upper arm, and rotating sites each week reduces the risk of lipohypertrophy, which is the buildup of fatty tissue that impairs drug absorption (Blanco et al., 2013, Diabetes Care).
Finally, if you are self-injecting for the first time, ask your prescriber or pharmacist to walk you through the process with your actual pen, not a demo. The tactile difference is real and matters for confidence and safety.